Etubics Corporation is a wholly owned subsidiary of ImmunityBio, Inc. (formerly named NantCell, Inc.).
(“Etubics” or the “Company”) is a Seattle based biopharmaceutical company developing targeted immunotherapies and vaccine products for a wide range of resilient diseases. Etubics patent-protected technology has been proven to be safer, more efficient and more effective than current vectored vaccines and gene delivery platforms.
We specialize in developing innovative immunotherapies and vaccines utilizing our exclusive next-generation viral vector gene delivery technology and our patented manufacturing cell line, together known as the Etubics Platform.
The Etubics Platform delivers a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody. The Etubics Platform provides the following capabilities:
- Utilization of boosting
- Enhanced CMI response
- No unwanted viral replication in the body
- Treatment of multiple diseases in the same patient
- Convenient subcutaneous injection
NEXT GENERATION VACCINES
Etubics is developing innovative immunotherapies and vaccines utilizing our proprietary gene delivery platform and our patented human E.C7 human cell line – the Etubics Platform.
Etubics Corporation has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, a part of the National Institutes of Health, to investigate a multi-targeted immunotherapy approach containing three tumor-associated antigens including ETBX-011. These three antigens are highly expressed in various human carcinomas and the ability to simultaneously target all three could be of significant clinical benefit in terms of overall survival of cancer patients.
Find out more about our Technology